Monday, 31 August 2026European Markets

CROSSWOOD Stock Impressive Jump On Monday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with crosswood (cros.pa) rising 19.76% to €10.00 on monday while cac 40 dropped 0.48% to €7,013.73.

crosswood's last close was €8.35, 52.29% under its 52-week high of €17.50.

about crosswood

crosswood sa engages in real estate activity in france. its property portfolio includes shops and offices, and housing properties. the company was formerly known as desquenne et giral. crosswood sa was incorporated in 1935 and is based in paris, france. crosswood sa operates as a subsidiary of compagnie financiere de broceliande.

earnings per share

as for profitability, crosswood has a trailing twelve months eps of €-0.11.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.48%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on mar 6, 2023, the estimated forward annual dividend rate is 0.11 and the estimated forward annual dividend yield is 1.32%.

yearly top and bottom value

crosswood's stock is valued at €10.00 at 21:32 est, way under its 52-week high of €17.50 and way higher than its 52-week low of €6.65.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com